In response to compressed drug development timelines, oftentimes settling for sub-optimal dose form design and manufacturability considerations complicate downstream development steps.  To ensure the program remains on track for long-term market success, continuously reviewing the molecule’s material properties, pharmacokinetics, manufacturability, stability, product differentiation and patient considerations at each development stage is essential. Identifying and eliminating potential roadblocks early provides the best chance of a successful product launch, resulting in the biggest positive impact on patient health.

Join this webinar to hear experts present evidence on how the right guidance at the right time can help you create more successful treatments. The experts will introduce Catalent’s new OptiDose™ Design Solution, an integrated dose form design strategy based on an analyzation of your molecule, patient, and market. The experts explain how this solution delivers dose form recommendations that can help differentiate your product, improve customer acceptance, and turn your science into patient accepted and commercially successful medicines.

Key Learning Objectives:

  • Key considerations for pharmaceutical companies and biotech start-ups when engaging a consultant or scientific advisory on a long-term strategy.
  • Advantages of data-driven collaborative approaches to determine optimal dose forms.
  • Introduction to Catalent’s OptiDose Design Solution and insights into key patient considerations impacting dose form selection.
  • Learn how Catalent’s Scientific Advisors operationalize the assessment process within the overall drug development program, with example scenarios.

Featured Speakers

Alan F. Parr, Pharm.D., Ph.D


Dr. Parr is the former Director of Biopharmaceutics at GlaxoSmithKline and has held various roles including formulation scientist and formulation manager. He has worked in the field of pharmaceutical sciences for 33 years, where his responsibilities ranged from development of formulations from early development through to scale up of commercial-scale batches. Since 2015 Dr. Parr has served as consultant to numerous small pharmaceutical companies.

Lisa Caralli

Director Science & Technology
Catalent Pharma Solutions

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, Davis, California.


Register now for this webinar